Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

NCT02642965 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02642965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02642965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
May 2, 2016
Completion date
June 30, 2023
Enrollment
38 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia post cytotoxic therapy, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia